Stocks · News reference

HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

Oct 5, 2026, 12:03 PMBenzinga Newsdesk

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $8 price target.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Oct 5, 2026, 12:03 PM
Checked: Oct 5, 2026, 12:03 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaOct 1, 2026, 1:32 PMBenzinga Newsdesk
Gain Therapeutics Announces Poster Presentation At International Congress Of Parkinson’s Disease And Movement Disorders, October 4-8; MDS-UPDRS Motor Scores Demonstrated Stability To Baseline Recorded At Study Entry With No Disease Progression Among The 12 Evaluable Participants; Results Support Disease-Modifying Potential Of Rexaceract
GANX
BenzingaOct 1, 2026, 1:20 PMBenzinga Newsdesk
Gain Therapeutics Plans To Initiate Phase 2 Rexaceract Trial In Q1 Next Year
GANX
SEC EDGAROct 1, 2026, 1:16 PMSEC EDGAR
8-K filing — Gain Therapeutics, Inc. (GANX)
Filed: 2026-10-01 AccNo: 0001104659-26-112624 Size: 203 KB Item 8.01: Other Events
GANX